ASRT - Assertio Therapeutics Inc Stock Price, Fair Value and News

0.83USD+0.04 (+5.06%)Market Closed

Market Summary

USD0.83+0.04

Market Closed

5.06%

ASRT Stock Price

View Fullscreen

ASRT RSI Chart

ASRT Valuation

Market Cap

78.8M

Price/Earnings (Trailing)

-0.24

Price/Sales (Trailing)

0.52

EV/EBITDA

-0.2

Price/Free Cashflow

1.61

ASRT Price/Sales (Trailing)

ASRT Profitability

EBT Margin

-167.06%

Return on Equity

-240.53%

Return on Assets

-115.89%

Free Cashflow Yield

62.12%

ASRT Fundamentals

ASRT Revenue

Revenue (TTM)

152.1M

Rev. Growth (Yr)

-34.49%

Rev. Growth (Qtr)

-7.42%

ASRT Earnings

Earnings (TTM)

-331.9M

Earnings Growth (Yr)

-164.8%

Earnings Growth (Qtr)

79.47%

Breaking Down ASRT Revenue

Last 7 days

7.8%

Last 30 days

-16.2%

Last 90 days

-5.7%

Trailing 12 Months

-83.7%

How does ASRT drawdown profile look like?

ASRT Financial Health

Current Ratio

1.83

Debt/Equity

0.28

Debt/Cashflow

1.29

ASRT Investor Care

Shares Dilution (1Y)

70.92%

Diluted EPS (TTM)

-4.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	162.2M	168.0M	169.4M	152.1M
2022	120.7M	130.5M	139.2M	156.2M
2021	112.2M	117.0M	107.9M	111.0M
2020	198.7M	167.9M	137.1M	106.3M
2019	0	0	0	229.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Assertio Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2024	tyree james l	sold	-11,462	1.1182	-10,251	-
Feb 21, 2024	patel ajay	acquired	-	-	17,151	svp and cfo
Feb 21, 2024	schwichtenberg paul	sold (taxes)	-6,719	0.79	-8,506	svp, cco
Feb 21, 2024	schlessinger sam	sold (taxes)	-6,719	0.79	-8,506	svp, general counsel
Feb 21, 2024	schlessinger sam	acquired	-	-	17,151	svp, general counsel
Feb 21, 2024	schwichtenberg paul	acquired	-	-	17,151	svp, cco
Feb 21, 2024	patel ajay	sold (taxes)	-6,719	0.79	-8,506	svp and cfo
Feb 11, 2024	schwichtenberg paul	acquired	-	-	47,348	see remarks
Feb 11, 2024	schlessinger sam	acquired	-	-	18,939	svp, general counsel
Feb 11, 2024	patel ajay	acquired	-	-	47,348	svp and cfo

Which funds bought or sold ASRT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Allworth Financial LP	reduced	-85.83	-231	34.00	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	0.8	-1,000	13,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-12.9	-156,675	558,432	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	added	95.5	16,000	37,000	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	-14.00	120	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-71.33	-5,000	2,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	sold off	-100	-120,131	-	-%
Apr 19, 2024	CONTINENTAL GENERAL INSURANCE CO	sold off	-100	-5,456,880	-	-%
Apr 19, 2024	DENALI ADVISORS LLC	added	286	112,787	158,476	0.05%
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	-	-	-%

Are Funds Buying or Selling ASRT?

Are funds buying ASRT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ASRT

No. of Funds

Unveiling Assertio Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	continental general insurance co	-	0	SC 13G/A
Feb 14, 2024	armistice capital, llc	6.13%	5,800,000	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	8.0%	7,619,440	SC 13G
Feb 13, 2024	vanguard group inc	5.15%	4,878,543	SC 13G
Jan 26, 2024	blackrock inc.	6.9%	6,574,483	SC 13G
May 05, 2023	continental general insurance co	6.7%	96,426	SC 13G
Jan 27, 2022	highbridge capital management llc	0%	0	SC 13G/A
Feb 16, 2021	d. e. shaw & co, l.p.	2.2%	2,321,422	SC 13G/A
Feb 11, 2021	renaissance technologies llc	6.08%	6,522,314	SC 13G/A
Feb 04, 2021	ci investments inc.	5.63%	6,258,862	SC 13G/A

Recent SEC filings of Assertio Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	EFFECT	EFFECT
Apr 19, 2024	ARS	ARS
Apr 19, 2024	DEF 14A	DEF 14A
Apr 09, 2024	3	Insider Trading
Apr 09, 2024	PRE 14A	PRE 14A
Apr 02, 2024	8-K	Current Report
Mar 27, 2024	8-K	Current Report
Mar 15, 2024	4	Insider Trading
Mar 14, 2024	144	Notice of Insider Sale Intent
Mar 12, 2024	8-K/A	Current Report

Peers (Alternatives to Assertio Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	352.0B	85.2B	-7.49%	-10.35%	10.01	4.13	6.46%	95.94%
MRK	332.3B	60.1B	-0.42%	13.93%	910.36	5.53	1.40%	-97.49%
AMGN	144.7B	28.2B	-5.70%	12.33%	21.54	5.13	7.09%	2.52%
PFE	143.3B	46.5B	-8.64%	-34.49%	-103.22	3.08	42.59%	-114.62%
GILD	81.5B	27.1B	-10.34%	-21.65%	14.4	3.01	-0.60%	23.36%
TEVA	15.4B	15.8B	-4.37%	61.97%	-26.83	0.97	6.17%	76.47%
MID-CAP
PRGO	4.3B	4.7B	1.49%	-12.83%	-340.71	0.93	4.58%	90.97%
ALKS	4.1B	1.7B	-9.36%	-12.84%	11.6	2.48	49.61%	324.78%
BHC	3.2B	8.8B	-16.97%	22.33%	-5.38	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-5.51%	13.03%	14.38	3.07	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-28.23%	-25.52%	-3.91	1.85	24.65%	80.36%
TXMD	21.5M	1.3M	-17.33%	-48.76%	-2.09	16.47	-98.14%	-109.18%
ACRX	17.8M	-	-4.55%	55.56%	-0.97	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	8.11%	-93.94%	-0.19	0.14	80.00%	43.08%
ACOR	906.7K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Assertio Therapeutics Inc News

Latest updates

Assertio Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-7.4%	32,985,000	35,627,000	40,991,000	42,466,000	50,351,500	34,212,000	35,131,000	36,538,000	33,329,000	25,472,000	25,373,000	26,839,000	30,176,000	34,565,000	20,617,000	20,917,000	38,032,000	55,147,000	57,203,000
Costs and Expenses	-75.3%	65,314,000	263,898,000	28,571,000	37,822,000	39,730,000	27,778,000	24,340,000	24,979,000	25,346,500	19,538,000	37,374,000	19,332,000	63,272,000	41,240,000	46,369,000	37,549,000	-	65,280,000	53,585,000
S&GA Expenses	14.1%	23,958,000	21,005,000	16,771,000	16,904,000	13,703,500	11,900,000	10,543,000	10,638,000	11,264,000	9,013,000	24,040,000	8,324,000	21,272,000	27,607,000	28,131,000	27,314,000	-	36,117,000	24,755,000
R&D Expenses	-22.2%	1,024,000	1,316,000	503,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	-Infinity%	-1.45	-	0.35	0.35	0.47	0.47	0.51	0.37	0.35	-0.02	-0.14	-0.43	-0.03	-	-	-	-	-	-
Interest Expenses	-	4,398,000	-	-	1,122,000	-1,163,500	-	-	2,327,000	2,436,500	2,495,000	2,605,000	2,684,000	2,598,000	3,050,000	1,604,000	8,674,000	-	13,872,000	14,842,000
Income Taxes	-49.8%	25,458,500	50,700,000	3,860,000	-2,110,000	-79,975,000	210,000	593,000	713,000	434,000	46,000	-300,000	548,000	-10,995,000	1,050,000	-9,472,000	2,048,000	-	-1,715,000	1,141,000
Earnings Before Taxes	86.1%	-31,905,000	-228,885,000	12,330,000	-5,594,000	8,578,000	4,384,000	8,427,000	9,777,000	5,040,500	3,783,000	-14,469,000	5,092,000	-35,348,000	-9,472,000	-43,971,000	43,278,000	-	1,616,000	-12,464,000
EBT Margin	-32.5%	-1.67	-1.26	0.12	0.10	0.20	0.20	0.21	0.03	0.00	-0.38	-0.46	-0.75	-	-	-	-	-	-	-
Net Income	79.5%	-57,384,000	-279,544,000	8,470,000	-3,484,000	88,553,000	4,174,000	7,834,000	9,064,000	4,606,500	3,737,000	-14,169,000	4,544,000	-24,353,000	-10,522,000	-34,499,000	41,230,000	-192,626,000	3,331,000	-13,605,000
Net Income Margin	-98.8%	-2.18	-1.10	0.58	0.60	0.70	0.18	0.19	0.03	-0.01	-0.28	-0.38	-0.58	-	-	-	-	-	-	-
Free Cashflow	117.4%	5,607,000	2,579,000	18,327,000	22,443,000	26,423,000	10,045,000	14,377,000	27,373,000	4,078,000	4,654,000	964,000	-4,226,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-24.6%	286	380	405	414	414	323	322	339	327	299	312	325	303	333	346	527
Current Assets	-7.5%	171	185	134	138	132	126	117	125	103	113	119	124	94.00	104	135	104
Cash Equivalents	-4.5%	73.00	77.00	70.00	69.00	65.00	65.00	52.00	61.00	37.00	59.00	54.00	61.00	21.00	35.00	59.00	42.00
Inventory	-11.8%	38.00	43.00	19.00	16.00	14.00	14.00	12.00	9.00	7.00	5.00	7.00	9.00	12.00	13.00	25.00	3.00
Net PPE	-4.2%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	4.00	7.00	3.00
Goodwill	-100.0%	-	20.00	-	-	-	-	-	-	-	-	-	-	-	9.00	9.00	-
Liabilities	-20.7%	148	187	151	164	188	188	194	227	224	202	220	220	248	257	261	469
Current Liabilities	-18.2%	93.00	114	79.00	95.00	95.00	92.00	116	139	135	100	117	109	133	131	134	185
Long Term Debt	-0.9%	39.00	39.00	38.00	38.00	66.00	66.00	50.00	61.00	61.00	66.00	67.00	72.00	72.00	77.00	92.00	271
LT Debt, Current	-	-	-	-	0.00	0.00	-	-	-	12.00	-	-	-	12.00	-	-	80.00
LT Debt, Non Current	-0.9%	39.00	39.00	38.00	38.00	66.00	66.00	50.00	61.00	61.00	66.00	67.00	72.00	72.00	77.00	92.00	271
Shareholder's Equity	-28.4%	138	193	254	251	226	135	128	112	102	97.00	92.00	105	56.00	76.00	85.00	58.00
Retained Earnings	-9.7%	-651	-594	-314	-323	-319	-408	-412	-420	-429	-433	-437	-423	-427	-403	-393	-399
Additional Paid-In Capital	0.3%	790	787	569	574	545	543	541	532	532	531	530	529	483	480	478	458
Shares Outstanding	0.1%	95.00	95.00	57.00	56.00	48.00	48.00	46.00	45.00	45.00	43.00	41.00	38.00	-	-	-	-
Float	-	-	-	296	-	-	-	140	-	-	-	68.00	-	-	-	90.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	121.3%	5,707	2,579	18,601	22,717	26,697	10,045	14,430	27,426	4,131	4,654	964	-4,226	-5,982	-14,431	-20,096	-25,063	-	-	-
Share Based Compensation	41.7%	2,642	1,865	2,205	2,446	2,388	2,400	1,734	982	949	867	957	772	3,886	1,511	3,593	1,934	-	-	-
Cashflow From Investing	-105.8%	-239	4,144	-703	-105	-25,784	-371	-16,114	-404	-18,525	-	-	-	-	-1.00	63,766	449,036	-	-	-
Cashflow From Financing	-89050.0%	-8,915	-10.00	-16,326	-18,950	-798	2,888	-7,441	-2,443	-7,522	-356	-7,569	44,473	-7,969	-10,234	-90,240	-360,107	-	-	-

ASRT Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenues	$ 152,069	$ 156,234
Costs and expenses:
Cost of sales	27,020	18,748
Research and development expenses	2,843	0
Selling, general and administrative expenses	78,638	46,786
Change in fair value of contingent consideration	(25,538)	18,687
Amortization of intangible assets	27,527	32,608
Loss on impairment of intangible assets	279,639	0
Restructuring charges	5,476	0
Total costs and expenses	395,605	116,829
(Loss) income from operations	(243,536)	39,405
Other (expense) income:
Debt related expenses	(9,918)	0
Interest expense	(3,380)	(7,961)
Other gain (loss)	2,780	(278)
Total other expense	(10,518)	(8,239)
Net (loss) income before income taxes	(254,054)	31,166
Income tax (expense) benefit	(77,888)	78,459
Net (loss) income	(331,942)	109,625
Comprehensive (loss) income	$ (331,942)	$ 109,625
Basic net (loss) income per share (in dollars per share)	$ (4.67)	$ 2.33
Diluted net (loss) income per share (in dollars per share)	$ (4.67)	$ 2.03
Shares used in computing basic net (loss) income per share (in shares)	71,031	47,004
Shares used in computing diluted net (loss) income per share (in shares)	71,031	54,669
Product sales, net
Revenues:
Total revenues	$ 149,451	$ 155,121
Royalties and milestones
Revenues:
Total revenues	2,433	2,403
Other revenue
Revenues:
Total revenues	$ 185	$ (1,290)

ASRT Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 73,441	$ 64,941
Accounts receivable, net	47,663	45,357
Inventories, net	37,686	13,696
Prepaid and other current assets	12,272	8,268
Total current assets	171,062	132,262
Property and equipment, net	770	744
Intangible assets, net	111,332	197,996
Deferred tax asset	0	80,202
Other long-term assets	3,255	2,709
Total assets	286,419	413,913
Current liabilities:
Accounts payable	13,439	5,991
Accrued rebates, returns and discounts	58,137	49,426
Accrued liabilities	18,213	12,181
Long-term debt, current portion	0	470
Contingent consideration, current portion	2,700	26,300
Other current liabilities	954	948
Total current liabilities	93,443	95,316
Long-term debt	38,514	66,403
Contingent consideration	0	22,200
Other long-term liabilities	16,459	4,269
Total liabilities	148,416	188,188
Commitments and contingencies (Note 15)
Shareholders’ equity:
Common stock, $0.0001 par value, 200,000,000 shares authorized; 94,668,523 and 48,319,838 shares issued and outstanding as of December 31, 2023 and 2022, respectively	9	5
Additional paid-in capital	789,537	545,321
Accumulated deficit	(651,543)	(319,601)
Total shareholders’ equity	138,003	225,725
Total liabilities and shareholders' equity	$ 286,419	$ 413,913

About Assertio Therapeutics Inc

Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

CEO	Mr. Daniel A. Peisert
WEBSITE	assertiotx.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	30

Assertio Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Assertio Therapeutics Inc? What does ASRT stand for in stocks?

ASRT is the stock ticker symbol of Assertio Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Assertio Therapeutics Inc (ASRT)?

As of Fri Apr 26 2024, market cap of Assertio Therapeutics Inc is 78.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ASRT stock?

You can check ASRT's fair value in chart for subscribers.

What is the fair value of ASRT stock?

You can check ASRT's fair value in chart for subscribers. The fair value of Assertio Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Assertio Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ASRT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Assertio Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ASRT is over valued or under valued. Whether Assertio Therapeutics Inc is cheap or expensive depends on the assumptions which impact Assertio Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ASRT.

What is Assertio Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, ASRT's PE ratio (Price to Earnings) is -0.24 and Price to Sales (PS) ratio is 0.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ASRT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Assertio Therapeutics Inc's stock?

In the past 10 years, Assertio Therapeutics Inc has provided -0.341 (multiply by 100 for percentage) rate of return.